Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses

David Schairer, Luis R. Martinez, Karin Blecher, Jason Chouake, Parimala Nacharaju, Philip Gialanella, Joel M. Friedman, Joshua D. Nosanchuk, Adam Friedman

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Nitric oxide (NO) is a critical component of host defense against invading pathogens; however, its therapeutic utility is limited due to a lack of practical delivery systems. Recently, a NO-releasing nanoparticulate platform (NO-np) was shown to have in vitro broad-spectrum antimicrobial activity and in vivo pre-clinical efficacy in a dermal abscess model. To extend these findings, both topical (TP) and intralesional (IL) NO-np administration was evaluated in a MRSA intramuscular murine abscess model and compared with vancomycin. All treatment arms accelerated abscess clearance clinically, histologically, and by microbiological assays on both days 4 and 7 following infection. However, abscesses treated with NO-np via either route demonstrated a more substantial, statistically significant decrease in bacterial survival based on colony forming unit assays and histologically revealed less inflammatory cell infiltration and preserved muscular architecture. These data suggest that the NO-np may be an effective addition to our armament for deep soft tissue infections.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
JournalVirulence
Volume3
Issue number1
DOIs
StatePublished - 2012

Keywords

  • MRSA
  • Nanotechnology
  • Nitric oxide
  • Pyomyositis

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Nitric oxide nanoparticles: Pre-clinical utility as a therapeutic for intramuscular abscesses'. Together they form a unique fingerprint.

  • Cite this